Challenging the current paradigm of melanoma progression: Brain metastasis as isolated first visceral site

Neuro-Oncology

Volumn 14, Issue 7, 2012, Pages 849-858

  Ma, Michelle W ^a   Qian, Meng ^a   Lackaye, Daniel J ^a   Berman, Russell S ^a,b   Shapiro, Richard L ^a,b   Pavlick, Anna C ^a,b   Golfinos, John G ^a,b   Parker, Erik C ^a,b   Darvishian, Farbod ^a   Hernando, Eva ^a   Shao, Yongzhao ^a   Osman, Iman ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

brain neoplasms; melanoma; neoplasm metastasis; neoplasm staging

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MITOSIS; PHENOTYPE; PREVALENCE; PRIMARY TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84862849653     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos113     Document Type: Article

References (32)

1. Kohler BA, Ward E, McCarthy BJ, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011;103(9):714-736.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.
3. Chamberlain MC. Brain metastases: a medical neuro-oncology perspective. Expert Rev Neurother. 2010;10(4):563-573.
4. Sloan AE, Nock CJ, Einstein DB. Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control. 2009;16(3): 248-255.
5. Aragon-Ching JB, Zujewski JA. CNS metastasis: an old problem in a new guise. Clin Cancer Res. 2007;13(6):1644-1647. (Pubitemid 46952929)
6. Deeken JF, Lö scher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007;13(6):1663-1674. (Pubitemid 46952931)
7. Cruz-Muñ oz W, Kerbel RS. Preclinical approaches to study the biology and treatment of brain metastases. Semin Cancer Biol. 2011;21(2): 123-130.
8. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655-661.
9. Gaspar LE, Chansky K, Albain KS, et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol. 2005;23(13):2955-2961. (Pubitemid 46224114)
10. Niwiń ska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol. 2010;21(5):942-948.
11. Carey LA, Ewend MG, Metzger R, et al. Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res Treat. 2004;88(3):273-280. (Pubitemid 40137306)
12. Boogerd W, Hart AA, Tjahja IS. Treatment and outcome of brain metastasis as first site of distant metastasis from breast cancer. J Neurooncol. 1997;35(2):161-167. (Pubitemid 27361686)
13. Kastritis E, Efstathiou E, Gika D, et al. Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy. Int J Gynecol Cancer. 2006;16(3):994-999. (Pubitemid 43886716)
14. Choo BA, Walji N, Spooner D, Barber P, Fernando IN. Prolonged relapsefree survival in two patients with an isolated brain metastasis from epithelial ovarian carcinoma. J Clin Oncol. 2010;28(17):e271-e272. http://jco. ascopubs.org/content/28/17/e271.full.pdf. Accessed February 8, 2012.
15. Shuch B, La Rochelle JC, Klatte T, et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer. 2008;113(7):1641-1648.
16. Cohn DA, Stuart-Harris R. Isolated central nervous system relapse of non-seminomatous germ cell tumour of the testis. A case report and review of the literature. Oncology. 2001;61(3):184-188. (Pubitemid 34701531)
17. Hayashi T, Igarashi K, Tanizawa A, Terada Y, Sekine H. Brain metastasis as a sole recurrence of prostate cancer after total prostatectomy. Urol Int. 1998;60(2):121-123. (Pubitemid 28142951)
18. Arepally G, Kenyon LC, Lavi E. Late onset of isolated central nervous system metastasis of liposarcoma-a case report. Am J Clin Oncol. 1996;19(4):351-355. (Pubitemid 26242230)
19. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978;42(2):660-668. (Pubitemid 8405861)
20. Cohn-Cedermark G, Ma° nsson-Brahme E, Rutqvist LE, Larsson O, Johansson H, Ringborg U. Central nervous system metastases of cutaneous malignant melanoma-a population-based study. Acta Oncol. 1998;37(5):463-470. (Pubitemid 28505988)
21. Sampson JH, Carter JH, Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88(1):11-20. (Pubitemid 28018958)
22. Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22(7):1293-1300. (Pubitemid 41079844)
23. Staudt M, Lasithiotakis K, Leiter U, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer. 2010;102(8):1213-1218.
24. Zakrzewski J, Geraghty LN, Rose AE, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer. 2011;117(8):1711-1720.
25. Kopf AW, Gross DF, Rogers GS, et al. Prognostic index for malignant melanoma. Cancer. 1987;59(6):1236-1241. (Pubitemid 17040410)
26. Wich LG,HamiltonHK, Shapiro RL, et al. Developing amultidisciplinary prospective melanoma biospecimen repository to advance translational research. Am J Transl Res. 2009;1(1):35-43. http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2776290/?tool=pubmed. Accessed February 8, 2012.
27. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36): 6199-6206.
28. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
29. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
30. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865-2872. (Pubitemid 41079905)
31. Dummer R, Rinderknecht J, Goldinger SM, et al. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases [abstract]. J Clin Oncol. 2011;29(15)(suppl-May 20, 2011):abstr 8548.
32. Long GV, Kefford RF, Carr PJA, et al. Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (mut) BRAF kinase: evidence of activity in melanoma brain metastases (mets) [abstract]. Ann Oncol. 2010;21(suppl 8):viii12.